Viruses, Vol. 14, Pages 1103: In Silico Evaluation of Paxlovid & rsquo;s Pharmacometrics for SARS-CoV-2: A Multiscale Approach

Viruses, Vol. 14, Pages 1103: In Silico Evaluation of Paxlovid’s Pharmacometrics for SARS-CoV-2: A Multiscale Approach
Viruses doi: 10.3390/v14051103
Authors:
Ferenc A. Bartha
Nóra Juhász
Sadegh Marzban
Renji Han
Gergely Röst

Paxlovid is a promising, orally bioavailable novel drug for SARS-CoV-2 with excellent safety profiles. Our main goal here is to explore the pharmacometric features of this new antiviral. To provide a detailed assessment of Paxlovid, we propose a hybrid multiscale mathematical approach. We demonstrate that the results of the present in silico evaluation match the clinical expectations remarkably well: on the one hand, our computations successfully replicate the outcome of an actual in vitro experiment; on the other hand, we verify both the sufficiency and the necessity of Paxlovid’s two main components (nirmatrelvir and ritonavir) for a simplified in vivo case. Moreover, in the simulated context of our computational framework, we visualize the importance of early interventions and identify the time window where a unit-length delay causes the highest level of tissue damage. Finally, the results’ sensitivity to the diffusion coefficient of the virus is explored in detail.

Source: Viruses - May 20, 2022 Category: Virology Authors: Ferenc A. Bartha N óra Juhász Sadegh Marzban Renji Han Gergely R öst Tags: Article Source Type: research